← All trials
NCT06823609
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2025
- Primary completion
- Nov 30, 2026
- Completion date
- Dec 31, 2027
- First posted
- Feb 12, 2025
- Last posted
- Feb 12, 2025
- Enrollment
- 180
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Qilu Pharmaceutical Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.